Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: hoffy who wrote (2849)	12/30/1998 10:34:00 PM
From: Tae Spam Kim	Read Replies (1) \| Respond to of 56535

Everyone come join us at the new "DayTrader's Haven" Messageboard in tigerinvestor.com discussion forum. I promise a friendly atmosphere in sharing our lessons, thoughts, tips, and adventures. -Tae Kim

To: hoffy who wrote (2849)	12/30/1998 10:43:00 PM
From: Spark	Read Replies (1) \| Respond to of 56535

Hoffy, As I confessed earlier got out because I don't seem to have the patience when I see the green, but am seriously thinking of going back in. From what I remember from a previous post the FDA rejection was expected before the buyout offer was made. Please anyone correct me if I'm wrong. If I'm wrong about that than I agree with your concerns Hoffy. Spark

To: hoffy who wrote (2849)	12/30/1998 11:32:00 PM
From: Bradpalm1	Read Replies (1) \| Respond to of 56535

Hoffy, I would first refer you to a post I made several weeks ago on the TokyoMex Cafe thread on Dec. 16th: <<To All: Many have questioned the validity of the ASCT buyout rumor by WLA (Parke-Davis) proposed earlier today by TM via e-mails to SA members and on this thread. I examined the plausibility of the rumor as it relates to the companies involved, their products, their goals as can best be determined and the current dynamics of the managed healthcare marketplace. WLA is a second tier but growing pharmaco who've recently prospered due to the tremendous success of their cholesterol-lowering agent Lipitor and less so due to the relative success of their Rezulin and Accupril products. They've recently released Omnicef, a once-a-day antibiotic which comes in a pleasant tasting strawberry pediatric suspension and Celexa, a new SSRI anti-depressant. WLA's drug pipeline is otherwise not too remarkable and they lack a large sales force comparable to companies such as PFE and MRK. They most recently have gone into marketing some OTC homeopathic remedies under the label of Quanterra products and a sales manager had told me that the company was exploring entering the pediatric marketplace last September. Those that have done some DD on Ascent Pediatrics (ASCT) know basically what the company is all about and so I won't reiterate it here. You should know that they currently successfully market Feverall and Pediamist and plan on releasing Primsol, a sulfa antibiotic and Orapred, a pleasant tasting prednisone product next year. Recently they broke a four year copromotion agreement with BMY to market the antibiotic Duracef in favor of a agreement with WLA to copromote their Omnicef. Due to this agreement they increased their sales forces by 34% in anticipation of the success of this antibiotic within the pediatric population and the release of their two new products next year. As I said before, ASCT is certainly a plum to be picked by any company wishing to expand their sales force (such as WLA), focuses on an specialty marketing (pediatrics) and wishes to aggressively broaden their customer base with a brand new and exciting product (Omnicef). WLA learned about marketing from the best drug marketers in the world when they copromoted Lipitor with PFE and their reps have often told me that they aimed to grow as marketers of products in the future. The fit between the two companies certainly works and would make sense if ASCT were looking to be acquired by a thriving and growing company. I gave this recommendation to Joe last evening and I strongly believe that in conjunction with the actual buyout rumor, this is a great potential intermediate play. Bradpalm1>> The NDA non-approval letter announced today was against a new extended release sprinkle formulation of their already FDA approved and very successful Feverall acetaminophen suppositories. The NDA can be resubmitted for a FDA consideration at a later time so I don't see this affecting the rumored merger talks. ASCT's Primsol and Orapred are still on track for FDA approval next year. Once again, the key to this rumored merger is WLA's apparent desire to now reach out to pediatricians through a strong marketing company like ASCT. Bradpalm1